Literature DB >> 27049797

Multiantigenic subunitary vaccines against tuberculosis in clinical trials: Where do we stand and where do we need to go?

Carolina Guapillo1, Rogelio Hernández-Pando1, Mario Alberto Flores-Valdez2.   

Abstract

The idea of presenting this commentary is to bring attention to the current status of clinical tests from several multiantigen vaccine candidates based on proteins produced by means of genetic engineering and molecular biology approaches and to suggest how new emerging technologies (OMICs) and bioinformatics might benefit vaccine development for better control of tuberculosis.

Entities:  

Keywords:  clinical trials; multiantigenic; tuberculosis; vaccines

Mesh：

Substances：

Year:  2016        PMID： 27049797      PMCID： PMC4963068          DOI： 10.1080/21645515.2015.1136760

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  20 in total

1.  Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis.

Authors:  J T Belisle; V D Vissa; T Sievert; K Takayama; P J Brennan; G S Besra
Journal:  Science       Date:  1997-05-30       Impact factor: 47.728

2.  The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.

Authors:  Hennie Geldenhuys; Helen Mearns; David J C Miles; Michele Tameris; David Hokey; Zhongkai Shi; Sean Bennett; Peter Andersen; Ingrid Kromann; Søren T Hoff; Willem A Hanekom; Hassan Mahomed; Mark Hatherill; Thomas J Scriba; Michele van Rooyen; J Bruce McClain; Robert Ryall; Guy de Bruyn
Journal:  Vaccine       Date:  2015-06-03       Impact factor: 3.641

3.  Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults.

Authors:  Isabel Leroux-Roels; Geert Leroux-Roels; Opokua Ofori-Anyinam; Philippe Moris; Els De Kock; Frédéric Clement; Marie-Claude Dubois; Marguerite Koutsoukos; Marie-Ange Demoitié; Joe Cohen; W Ripley Ballou
Journal:  Clin Vaccine Immunol       Date:  2010-09-22

4.  Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers.

Authors:  Jaap T van Dissel; Sandra M Arend; Corine Prins; Peter Bang; Pernille Nyholm Tingskov; Karen Lingnau; Jan Nouta; Michèl R Klein; Ida Rosenkrands; Tom H M Ottenhoff; Ingrid Kromann; T Mark Doherty; Peter Andersen
Journal:  Vaccine       Date:  2010-03-11       Impact factor: 3.641

Review 5.  New adjuvants for human vaccines.

Authors:  M Lamine Mbow; Ennio De Gregorio; Nicholas M Valiante; Rino Rappuoli
Journal:  Curr Opin Immunol       Date:  2010-05-11       Impact factor: 7.486

6.  First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.

Authors:  Angelique Kany Kany Luabeya; Benjamin M N Kagina; Michele D Tameris; Hennie Geldenhuys; Soren T Hoff; Zhongkai Shi; Ingrid Kromann; Mark Hatherill; Hassan Mahomed; Willem A Hanekom; Peter Andersen; Thomas J Scriba; Elisma Schoeman; Colleen Krohn; Cheryl L Day; Hadn Africa; Lebohang Makhethe; Erica Smit; Yolande Brown; Sara Suliman; E Jane Hughes; Peter Bang; Margaret A Snowden; Bruce McClain; Gregory D Hussey
Journal:  Vaccine       Date:  2015-06-19       Impact factor: 3.641

7.  Contagious diseases in the United States from 1888 to the present.

Authors:  Willem G van Panhuis; John Grefenstette; Su Yon Jung; Nian Shong Chok; Anne Cross; Heather Eng; Bruce Y Lee; Vladimir Zadorozhny; Shawn Brown; Derek Cummings; Donald S Burke
Journal:  N Engl J Med       Date:  2013-11-28       Impact factor: 91.245

8.  Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination coverage.

Authors:  V Romanus; H O Hallander; P Wåhlén; A M Olinder-Nielsen; P H Magnusson; I Juhlin
Journal:  Tuber Lung Dis       Date:  1995-08

9.  The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans.

Authors:  Kenneth Von Eschen; Royce Morrison; Madeleine Braun; Opokua Ofori-Anyinam; Els De Kock; Priya Pavithran; Marguerite Koutsoukos; Philippe Moris; Daniel Cain; Marie-Claude Dubois; Joe Cohen; W Ripley Ballou
Journal:  Hum Vaccin       Date:  2009-07-27

10.  Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting.

Authors:  Adam Penn-Nicholson; Hennie Geldenhuys; Wivine Burny; Robbert van der Most; Cheryl L Day; Erik Jongert; Philippe Moris; Mark Hatherill; Opokua Ofori-Anyinam; Willem Hanekom; Anne Bollaerts; Marie-Ange Demoitie; Angelique Kany Kany Luabeya; Evi De Ruymaeker; Michele Tameris; Didier Lapierre; Thomas J Scriba
Journal:  Vaccine       Date:  2015-06-10       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.